Discovery Labs (DSCO) Completes Enrollment of AEROSURF Trial; Will Cease Commercialization of SURFAXIN
Tweet Send to a Friend
Discovery Laboratories, Inc. (NASDAQ: DSCO) announced that it has completed enrollment in its AEROSURF® phase 2a clinical trial assessing the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
